Psychedelics Promote Structural and Functional Neural Plasticity Astral X Neural Plasticity, Alexandra C. Greb, Lindsay P. Cameron, Jonathan M. Wong, Eden V. Barragan, Paige C. Wilson, Kyle F. Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R. Padd, Whitney C. Duim, Megan Y. Dennis, A. Kimberley McAllister, Kassandra M. Ori-McKenney, John A. Gray and David E. Olson Experiment Findings, February 2018 https://www.researchgate.net/publication/331396378 SUMMARY Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the [...]
Lire la suiteAssessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Ayahuasca post-acute effects Regular Research Article Frederic Sampedro, Mario de la Fuente Revenga, Marta Valle, Natalia Roberto, Elisabet Domínguez-Clavé, Matilde Elices, Luís Eduardo Luna, José Alexandre S. Crippa, Jaime E. C. Hallak, Draulio B. de Araujo, Pablo Friedlander, Steven A. Barker, Enrique Álvarez, Joaquim Soler, Juan C. Pascual, Amanda Feilding and Jordi Riba © The Author 2017. Published by Oxford University Press on behalf of CINP. The International Journal of Neuropsychopharmacology, 2017, 20, 9 DOI : 10.1093/ijnp/pyx036 Significance Statement Psychedelics are intriguing drugs that induce transient but intense [...]
Lire la suiteKetamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression D. Jeffrey Newport, M.D., M.S., M.Div., Linda L. Carpenter, M.D., William M. McDonald, M.D., James B. Potash, M.D., M.P.H., Mauricio Tohen, M.D., Dr.P.H., M.B.A., Charles B. Nemeroff, M.D., Ph.D., The APA Council of Research Task Force on Novel Biomarkers and Treatments American Journal of Psychiatry, 2015, 172, 950–966 doi: 10.1176/appi.ajp.2015.15040465 Objective : The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method : Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials [...]
Lire la suiteEfficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial Ella J. Daly, MD; Madhukar H. Trivedi, MD; Adam Janik, MD; Honglan Li, MD, PhD; Yun Zhang, PhD; Xiang Li, PhD; Rosanne Lane, MAS; Pilar Lim, PhD; Anna R. Duca, BSN; David Hough, MD; Michael E. Thase, MD; John Zajecka, MD; Andrew Winokur,MD, PhD; Ilona Divacka, MBA, MD; Andrea Fagiolini, MD; Wiesław J. Cubała, MD, PhD; István Bitter,MD, PhD; Pierre Blier,MD, PhD; Richard C. Shelton, MD; Patricio Molero,MD, PhD; Husseini Manji, MD;Wayne C. Drevets, MD; Jaskaran B. Singh, MD JAMA Psychiatry, [...]
Lire la suiteLa psychothérapie psychédélique est de retour M le magazine du Monde | 12.03.2015 Mescaline, ecstasy, psilocybine soigneront-ils la dépression, l’angoisse, l’autisme ou l’alcoolisme ? Des psychiatres américains explorent le potentiel thérapeutique de ces substances illicites. Par Stéphanie Chayet Engourdissement, d’abord. Puis grande fatigue, bâillements. Des images, très abstraites, comme de l’art moderne. Des motifs. Image d’un chat en train de mordiller le câble de freinage d’un vélo. Après ça ? Sentiment de ne pas m’aimer. Pas du tout. Puis je me demande : pourquoi je ne m’aimerais pas ? Il n’y a aucune raison. » Ainsi commence, mot pour mot, le « compte rendu d’expérience [...]
Lire la suiteEfficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study Vanina Popova, M.D., Ella J. Daly, M.D., Madhukar Trivedi, M.D., Kimberly Cooper, M.S., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Mazzucco, M.Sc., David Hough, M.D., Michael E. Thase, M.D., Richard C. Shelton, M.D., Patricio Molero, M.D., Ph.D., Eduard Vieta, M.D., Ph.D., Malek Bajbouj, M.D., Husseini Manji, M.D., Wayne C. Drevets, M.D., Jaskaran B. Singh, M.D. American Journal of Psychiatry in Advance, 2019 ajp.psychiatryonline.org doi: 10.1176/appi.ajp.2019.19020172 Objective : About one-third of patients with depression fail to achieve remission despite treatment with multiple [...]
Lire la suiteRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C. Andrade, Morgana M. Novaes, Jessica A. Pessoa, Sergio A. Mota-Rolim, Flávia L. Osório, Rafael Sanches, Rafael G. dos Santos, Luís Fernando Tófoli, Gabriela de Oliveira Silveira, Mauricio Yonamine7, Jordi Riba, Francisco R. Santos, Antonio A. Silva-Junior, João C. Alchieri10, Nicole L. Galvão-Coelho5,11, Bruno Lobão-Soares5,12, Jaime E. C. Hallak, Emerson Arcoverde, João P. Maia-de-Oliveira and Dráulio B. Araújo Psychological Medicine, June 2018, 1-9 https://www.cambridge.org/core doi.org/10.1017/S0033291718001356 Abstract Background. Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods. [...]
Lire la suite3,4-Methylenedioxymethamphetamine assisted psychotherapy for treatment of chronic posttraumatic stress disorder : A randomized phase 2 controlled trial Marcela Ot’alora G, Jim Grigsby, Bruce Poulter1, Joseph W Van Derveer III, Sara Gael Giron, Lisa Jerome, Allison A Feduccia, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C Mithoefer and Rick Doblin Journal of Psychopharmacology, 2018, 1-13 Doi : 10.1177/0269881118806297 Abstract Background : Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. Aims : This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Methods : [...]
Lire la suiteEndocannabinoid-Mediated Control of Synaptic Transmission Masanobu KANO, Takako OHNO-SHOSAKU, Yuki HASHIMOTODANI, Motokazu UCHIGASHIMA, and Masahiko WATANABE Physiological Reviews, 2009, 89, 1, 309-380. https://doi.org/10.1152/physrev.00019.2008 I. Introduction 310 II. Cannabinoid Receptors 311 A. CB1 receptor 311 B. CB2 receptor 315 C. “CB3” receptor 315 D. TRPV1 receptor 317 E. GPR55 receptor 317 III. CB1 Receptor Signaling 317 A. Intracellular signaling pathways 317 B. Suppression of transmitter release 318 C. Morphological changes 318 IV. Biochemistry of Endocannabinoids 318 A. Endocannabinoids 318 B. Biosynthesis of anandamide 319 C. Biosynthesis of 2-AG 320 D. Degradation of endocannabinoids 321 E. Endocannabinoid transport 321 F. Lipid raft 322 V. Endocannabinoid-Mediated Short-Term Depression 322 A. Endocannabinoid as a retrograde messenger 322 B. eCB-STD in various brain regions 324 C. Mechanisms of ecb-std 334 VI. [...]
Lire la suiteKetamine a Panacea for Resistant Depression? Not So Fast, Experts Say Nancy A. Melville April 04, 2019 https://www.medscape.com/viewarticle/911378#vp_3 CHICAGO — Ketamine's rapid antidepressant effects and its recent approval by the US Food and Drug Administration (FDA) has clinicians and patients alike buzzing with excitement. However, for some experts, this excitement only serves to heighten concerns about the many unknowns and potential long-term side effects of the drug, which began its long history as an anesthetic. Here, at the Anxiety and Depression Association of American (ADAA) 2019 Conference, experts debated the drug's merits and potential pitfalls. "These are exciting times and I think ketamine has opened a new era," Carlos [...]
Lire la suite